Imprimis Pharma (NASDAQ: IMMY) reported Q2 EPS of ($0.39), $0.07 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $2 million versus the consensus estimate of $2.13 million.

For earnings history and earnings-related data on Imprimis Pharma (IMMY) click here.